Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy.

Next Previous
Trial Profile

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms REMAGUS-02

    • Most Recent Events

    • 01 Mar 2018 Results of study assessing predictive role of COX2 gene transcripts for pathological response to neoadjuvant celecoxib published in the Anticancer Research
    • 06 Mar 2017 Results of long-term follow-up for disease-free survival and overall survival published in the European Journal of Cancer
    • 08 Dec 2012 Results for disease-free survival and overall survival in HER2 positive patients treated with or without trastuzumab presented at the 35th Annual San Antonio Breast Cancer Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top